Fig. 3From: Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker programKaplan-Meier curves for progression-free survival depending on VEGF-A at baseline dichotomized at the median 58.7 pg/l. Hazard ratio 0.533, 95 % CI 0.318–0.895, P = 0.017Back to article page